Semax: A Research Overview

Semax is one of the two best-known Russian nootropic peptides (the other is Selank). It is unusual in this library for having genuine pharmaceutical approval — but in Russia, not the United States — and a substantial clinical-use history there. That regional approval is real and worth stating accurately, while being equally clear that it is not an FDA approval and that most of the supporting evidence comes from a single national research tradition with limited independent Western replication.

This overview summarizes what the published literature reports about Semax — its structure, mechanism, evidence, and regulatory status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Semax Is

Semax is a synthetic heptapeptide (sequence Met-Glu-His-Phe-Pro-Gly-Pro) — an analog of a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) region extended with a Pro-Gly-Pro stabilizing tail. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s and is administered intranasally (Semax (ACTH(4-7)PGP) characterization, Int J Mol Sci (PMC)).

An important pharmacological point: although derived from ACTH, the fragment Semax is based on retains neurotropic activity but lacks the sequence required for adrenocortical stimulation — so, unlike ACTH itself, Semax does not elevate cortisol, ACTH, or aldosterone (Semax as melanocortin derivative (mechanism, PMC)). It was engineered to keep the brain effects while shedding the hormonal ones.

Mechanism — BDNF and Neuroplasticity

Semax’s most studied mechanism is upregulation of brain-derived neurotrophic factor (BDNF), a protein central to neuron survival, synapse formation, and neuroplasticity. In rat studies, intranasal Semax increased hippocampal BDNF mRNA within about 30 minutes (Semax BDNF/neuroprotective gene-expression study (PMC)). It also modulates dopaminergic and serotonergic signaling and, in a brain-ischemia model, altered expression of dozens of genes related to immune and vascular processes — consistent with its framing as a neuroprotective and cognition-supporting agent.

The Evidence Base and Russian Approval

In Russia, Semax is an approved prescription medication (0.1% nasal formulation) used for indications including cognitive disorders, stroke recovery, and optic nerve atrophy, and it has been included on the Russian List of Vital and Essential Drugs (Semax clinical stroke use (Int J Mol Sci, PMC)). That is a genuine regulatory and clinical-use history — more than most compounds in this library have.

The honest limitation: most published Semax data come from Russian research groups, and independent Western replication is limited (Semax literature concentrated in one research tradition (PMC)). It is not approved by the FDA or European regulators, and in the United States, it is classified as a research compound. So the accurate picture is real regional approval and clinical use, with an evidence base concentrated in one national tradition.

• Met-Glu-His-Phe-Pro-Gly-Pro; ACTH(4-7) analog without ACTH’s cortisol-stimulating activity.
• Approved and used clinically in Russia (nootropic/neuroprotective); not FDA- or EU-approved.
• Evidence concentrated in Russian research groups; limited independent Western replication.

Regulatory Status

The status below reflects mid-2026 and may change; verify before relying on it. Semax is not FDA-approved in the United States; it is classified and sold here as a research-grade compound for laboratory use only, by its labeling, not for human consumption. It holds prescription-drug status in Russia. (As with several peptides, US compounding status has been in flux during 2026; a compounding pathway, if it emerges, would not equal FDA approval.)

Why Semax Draws Research Interest

Semax is a well-studied (within its tradition) nootropic and neuroprotective peptide with a clear BDNF-centered mechanism, a real Russian clinical-use history, and a clean separation of neurotrophic from hormonal activity. The accurate framing is that it is a peptide with genuine regional approval and a substantial but largely single-tradition evidence base, no FDA approval, and US research-only status.

For deeper reading, the cited literature is the best starting point. Semax is most often discussed alongside its sister peptide — see the Selank overview — with which it shares an institute, a Pro-Gly-Pro stabilizer, and a complementary profile (cognition vs. anxiety). The wider class is collected in our peptide research library.